Sector Gamma AS Sells 25,439 Shares of Edwards Lifesciences Co. (NYSE:EW)

Sector Gamma AS reduced its stake in Edwards Lifesciences Co. (NYSE:EW) by 11.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 187,556 shares of the medical research company’s stock after selling 25,439 shares during the period. Edwards Lifesciences accounts for 3.5% of Sector Gamma AS’s holdings, making the stock its 13th biggest holding. Sector Gamma AS’s holdings in Edwards Lifesciences were worth $14,301,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Martin Capital Advisors LLP increased its position in shares of Edwards Lifesciences by 0.5% during the fourth quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock worth $1,944,000 after acquiring an additional 128 shares in the last quarter. Legacy Wealth Asset Management LLC increased its position in shares of Edwards Lifesciences by 0.8% during the fourth quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock worth $1,293,000 after acquiring an additional 134 shares in the last quarter. DMC Group LLC increased its position in shares of Edwards Lifesciences by 4.5% during the fourth quarter. DMC Group LLC now owns 3,561 shares of the medical research company’s stock worth $272,000 after acquiring an additional 154 shares in the last quarter. Granite Harbor Advisors Inc. increased its position in shares of Edwards Lifesciences by 4.2% during the third quarter. Granite Harbor Advisors Inc. now owns 3,832 shares of the medical research company’s stock worth $265,000 after acquiring an additional 155 shares in the last quarter. Finally, Stableford Capital II LLC grew its position in Edwards Lifesciences by 2.7% in the 4th quarter. Stableford Capital II LLC now owns 5,980 shares of the medical research company’s stock worth $449,000 after purchasing an additional 155 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Edwards Lifesciences news, Director Heisz Leslie Stone sold 7,056 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $86.45, for a total transaction of $609,991.20. Following the transaction, the director now owns 26,980 shares of the company’s stock, valued at $2,332,421. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 194,004 shares of company stock worth $17,166,254. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Stock Down 1.8 %

NYSE:EW traded down $1.58 on Friday, reaching $86.43. 4,979,943 shares of the stock traded hands, compared to its average volume of 2,883,164. The company has a market capitalization of $52.02 billion, a price-to-earnings ratio of 37.25, a PEG ratio of 4.36 and a beta of 1.05. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The company’s fifty day simple moving average is $90.28 and its 200 day simple moving average is $78.85.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 23.34%. The firm had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.58 billion. Equities analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on EW. Evercore ISI reduced their price objective on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating for the company in a research report on Friday. Mizuho increased their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, April 11th. Morgan Stanley increased their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, March 21st. Oppenheimer increased their price target on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, March 18th. Finally, Citigroup increased their price target on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a research report on Wednesday, April 3rd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $93.33.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.